U.S. Markets close in 6 hrs 23 mins

Poseida Therapeutics, Inc. (PSTX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
12.71+0.03 (+0.24%)
As of 9:37AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close12.68
Bid12.75 x 1200
Ask13.19 x 800
Day's Range12.56 - 13.18
52 Week Range11.35 - 17.62
Avg. Volume927,505
Market Cap785.68M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.22
  • Poseida Therapeutics Appoints Harry J. Leonhardt, Esq. as General Counsel
    PR Newswire

    Poseida Therapeutics Appoints Harry J. Leonhardt, Esq. as General Counsel

    Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company dedicated to utilizing proprietary gene engineering platform technologies to create next generation cell and gene therapeutics with the capacity to cure, today announced biotech veteran Harry J. Leonhardt, Esq. has joined the company as General Counsel and Chief Compliance Officer.

  • MarketWatch

    Poseida Therapeutics' stock opens higher, then seesaws around the IPO price

    Shares of Poseida Therapeutics Inc. kicked off their public life with a gain, after the biopharmaceutical company's initial public offering priced at the top of the expected range, but those gains quickly faded. The stock's first trade was at $17, or 6.3% above the $16 IPO price, at 11:09 a.m. Eastern for 1.1 million shares. The stock first traded below its IPO price at 11:12 a.m., and fell to an intraday low of $15.20, so far, before bouncing back above its IPO price. The company raised $204.8 million in the IPO after expenses. The stock has gone public at a time that the Renaissance IPO ETF run up 62.3% over the past three months, to outperform the S&P 500's 13.3% gain over the same period.